Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693315 · ClinicalTrials.gov registry record · Phase 2
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2 study of Glaucoma and Ocular Hypertension, sponsored by Amakem.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 6
- Study locations
NCT01693315: Completed Phase 2 study of Glaucoma and Ocular Hypertension, sponsored by Amakem.
NCT01693315 is a Phase 2 study of Glaucoma and Ocular Hypertension that has completed, run by Amakem. The registered enrollment target is 82 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01693315, a Phase 2 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Amakem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMA0076
Study Locations (6)
California
- Artesia Clinical Site - Site 02 - Artesia
- Inglewood Clinical Site - Site 03 - Inglewood
- Petaluma Clinical Site - Site 05 - Petaluma
Connecticut
- New Haven Clinical Site - Site 01 - New Haven
Georgia
- Atlanta Clinical Site - Site 04 - Atlanta
North Carolina
- High Point Clinical Site - Site 06 - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
What the finished NCT01693315 record still lists
NCT01693315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01693315 lists 6 locations in 4 states (California, Connecticut, Georgia).
Frequently Asked Questions
What is clinical trial NCT01693315 about?
NCT01693315 is a clinical study titled "Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma". The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
What is the current status of trial NCT01693315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2012-09. Estimated completion is 2013-07.
What conditions does trial NCT01693315 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension, Eye Disease.
What interventions are being tested in trial NCT01693315?
The interventions under investigation include: Placebo (DRUG), AMA0076 (DRUG).
Who is sponsoring clinical trial NCT01693315?
This trial is sponsored by Amakem, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01693315 being conducted?
This trial has 6 study locations across California, Connecticut, Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01693315's enrollment target sits among peer trials
82 49th of 92 higher than 44 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia